|Print Page Close Window|
|DURECT CORP filed this Form 8-K on 11/19/2018|
development, testing and regulatory approval of DUR-928, potential adverse effects arising from the testing or use of our drug candidates, and risks related to our ability to obtain capital to fund operations and expenses. Further information regarding these and other risks is included in DURECT's Form 10-Q filed on November 8, 2018 under the heading "Risk Factors."
SOURCE: DURECT Corporation
CONTACT:Michael Arenberg, Chief Financial Officer, DURECT Corporation, 408-346-1052